Sunday, 11 October 2015

08:30 - 10:45     Session 2D: Molecular Virology – Viral replication - host factors                       Salle Erasme
                          Session chairs: Raffaele DE FRANCESCO & Pablo GASTAMINZA

08:30 - 08:45     Primer Virus-Host Interactions
                          Takaji WAKITA, National Institute of Infectious Diseases, Tokyo, Japan

08:45 - 10:45 Session 2D oral abstracts

08:45 - 09:00 Human choline kinase alpha promotes HCV RNA replication through modulating membranous replication complex formation O2.19
  Mun-Teng WONG, Steve S CHEN  
09:00 - 09:15 Dissecting the roles of miR-122 in different steps of the HCV life cycle
  Philipp SCHULT, Volker LOHMANN  
09:15 - 09:30 Abrogating stimulation of the cellular lipid kinase PI4KA reveals an unexpected mode of hepatitis C virus cell culture adaptation
  Christian HARAK, Max MEYRATH, Ines ROMERO-BREY, Philipp SCHULT, Katharina ESSER-NOBIS, Mohsan SAEED, Charles M RICE, Ralf BARTENSCHLAGER, Volker LOHMANN  
09:30 - 09:45 A new role for lysophosphatidic acid signalling in hepatitis C virus replication and HCC pathogenesis O2.22
09:45 - 10:00 Prolactin regulatory element binding protein promotes the formation of HCV membranous replication compartment by interacting with NS4B O2.23
  Kong LINGBAO, Fujimoto AKIRA, Aoyagi HARUYO, Matsuda MAMI, Watashi KOICHI, Suzuki RYOSUKE, Yamagoe SATOSHI, Dohmae NAOSHI, Suzuki TAKEHIRO, Suzuki TETSURO, Takaji Wakita, Aizaki HIDEKI  
10:00 - 10:15 Lipid-free apolipoprotein E induces an ABCG1 driven cholesterol efflux that markedly decreases HCV replication O2.24
  Emilie CROUCHET, Mathieu LEFEVRE, Eloi VERRIER, Thomas F BAUMERT, Catherine SCHUSTER  
10:15 - 10:30 miR-135a enhances hepatitis C virus genome replication by direct interacting with viral genome and downregulating antiviral host factors O2.25
  Catherine SODROSKI, Qisheng LI, T Jake Liang  
10:30 - 10:45 Requirement of miR-122 and miR-194 for efficient replication of hepatitis C virus in mouse hepatocytes O2.26
  Kyung-Don KANG, Guangxiang George LUO  


10:45 - 11:15     Refreshment Break                                                                                            Forum

11:15 - 13:00     Session 3A: Pathogenesis
                          Session chairs: Mirjam B ZEISEL & Jane A McKEATING

11:15 - 11:30     Primer Pathogenesis
                          Francesco NEGRO, Geneva University Hospitals, Geneva, Switzerland

11:30 - 13:00 Session 3A oral abstracts

11:30 - 11:45 Activation of liver-enriched transcription factor CREBH induced by HCV infection plays a key role in up-regulation of TGF-β2 expression and fibrogenesis O3.01
  Takeshi CHIDA, Masahiko ITO, Kenji NAKAJIMA, Tetsuro SUZUKI  
11:45 - 12:00 Hepatitis C virus replication induces and depends on a tumor-like glutamine metabolism
  Pierre L LEVY, Hannah EISCHEID, Maud MICHELETE, Sarah DUPONCHEL, Jennifer MOLLE, Hans-Michael STEFFEN, Fabien ZOULIM, Margarete ODENTHAL, Birke BARTOSCH  
12:00 - 12:15 Deciphering epigenetic reprogramming in persistent hepatitis C virus infection reveals candidate drivers of hepatocarcinogenesis
  Simonetta BANDIERA, Nourdine HAMDANE, Mirjam B ZEISEL, Yujin HOSHIDA, Nabeel BARDEESY, Thomas F BAUMERT  
12:15 - 12:30 Diminished hepatitis C virus replication within hepatocellular carcinoma tissue correlates with high viral diversity and malignant cell proliferation
  Djamila HAROUAKA, Ronald E ENGLE, Kurt WOLLENBERG, Giacomo DIAZ, Ashley TICE, Fausto ZAMBONI, Sugantha GOVINDARAJAN, Harvey J ALTER, David E KLEINER, Patrizia FARCI  
12:30 - 12:45 Inhibition of the insulin-mediated AS160 activation is an important event leading to increased HCV egress O3.05
  Sophie CLEMENT, Vincent KADDAI, Emilie BRANCHE, Stephanie CONZELMANN, Karim BOUZAKRI, Clotilde PARISOT, Francesco NEGRO  
12:45 - 13:00

Mechanisms of HCV-induced diabetes through impaired insulin-driven gluconeogenesis shut-down
by HCV proteins as a result of uncoupling of Foxo1/AKT signaling

  Hervé LERAT, Mohamed IMACHE, Jacqueline POLYTE, Aurore GAUDIN, Christophe MAGNAN, Fabienne FOUFELLE, Jean-Michel PAWLOTSKY  


13:00 - 14:30     Lunch                                                                                                                 Galerie de Marbre

14:30 - 16:30     Session 3B: Pathogenesis
                          Session chairs: Thomas F BAUMERT & Jin ZHONG

14:30 – 15:00 Plenary lecture: Jessica ZUCMAN-ROSSI

jessica zucman rossiGenomics of human hepatocellular carcinoma: mechanism of malignant transformation, signature of risk factors and therapeutic targets
Jessica Zucman-Rossi, MD, PhD, Professor of Oncology, University Paris Descartes, Director of the Inserm Unit “Functional Genomic of Solid Tumors”, UMRS-1162, Paris, France

Prof. Zucman-Rossi’s group has pioneered in the elucidation of the molecular classification of benign and malignant liver tumors. Prof. Zucman-Rossi leads the French liver tumor project in the International Cancer Genome Consortium (ICGC). Currently, she is chairman of the scientific committee “Genetic, Epigenetic and Cancer” at Inserm, member of the ILCA (International Liver Cancer Association) governing board and future executive secretary (2015-2018), she acts as co-Editor for Journal of Hepatology.
Hepatocellular carcinoma (HCC) is one of the leading causes of death by cancer worldwide. It is mainly developed on cirrhosis due to chronic hepatitis B and C, metabolic and alcoholic liver diseases in western countries. In contrast, hepatocellular adenomas are rare benign liver tumors frequently developed in women after oral contraception. Recent advances in molecular classification and dissection of genetic and epigenetic drivers have increased our knowledge of the molecular diversity of benign and malignant liver tumors. Using genomic approaches, we identified several new oncogenes and tumor suppressor genes and we described a molecular classification of hepatocellular adenomas that is used in clinical routine. Recently, using sequencing, we identified TERT promoter mutations activating telomerase as the most important mechanism of malignant transformation of both adenoma in carcinoma and of cirrhotic nodules in carcinoma. We also found new etiological factors predisposing to liver tumor development and new drug targets.


15:00 - 16:30 Session 3B oral abstracts

15:00 - 15:15 The hepatitis C virus NS5A protein antagonizes human transcripts that control cell growth and apoptosis by binding to GU-rich elements O3.07
  Suresh SHARMA, Daniel BEISANG, Liang GUO, Irina ST LOUIS, Jose DEBES, Jamie ARNOLD, Paul BOHJANEN, Craig CAMERON  
15:15 - 15:30 TRC8-dependent proteasome degradation of immature core protein participates in pathogenesis of HCV
  Toru OKAMOTO, Yukari SUGIYAMA, Takahisa KOUWAKI, Ayano ITO, Takasuke FUKUHARA, Kohji MORIISHI, Kazuhiko KOIKE, Yoshiharu MATSUURA  
15:30 - 15:45 Paracrine intercellular communication in HCV-driven disease
  Marie MOREAU, Benjamin RIVIèRE, Fernande SIADOUS, Marion PETER, Patricia CAVELIER, Jeanne RAMOS, Edouard BERTRAND, Eric ASSENAT, Urszula HIBNER  
15:45 - 16:00 MicroRNA profiling in liver cells unravels HCV-induced up-regulation of miR-146a-5p in hepatocytes
  Sophie PERNOT, Simonetta BANDIERA, Sarah C DURAND, Tao YE, Christine THUMANN, Beatrice CHANE-WOON-MING, Pasi KAUKINEN, Isabel FOFANA, Markus H HEIM, Sébastien PFEFFER, Thomas F BAUMERT, Mirjam B ZEISEL  
16:00 - 16:15 Ethanol increases the production of HCV lipo-viro-particles O3.11
  Véronique PENE, Céline HERNANDEZ, Etienne BLANC, Lynda AOUDJEHANE, Béatrice LEGRAND, Arnaud CARPENTIER, Jean-François MERITET, Filomena CONTI, Yvon CALMUS, Hélène ROUACH, Philippe PODEVIN, Arielle R ROSENBERG  
16:15 - 16:30 Interplay between hepatitis C virus and the circadian clock O3.12
  Xiaodong ZHUANG, Ke HU, Ben SAER, Peter BALFE, Janet LORD, Andrew LOUDON, Jane A McKEATING  


16:30 - 18:30     Poster Session II                                                                                                Forum
Beer & snacks